Steven Breazzano
Steven Breazzano
Stop FollowingSteven Breazzano
View as an RSS Feed
View Steven Breazzano's Articles BY TICKER:
- Obesity Sector Update And Compelling Short Opportunity
- 4 Biotechs Targeting Fibrosis
- Raptor Pharmaceuticals: Stock Below Fair Value With Recent Pullback
- NPS Pharmaceuticals: Misunderstood Assets And Compelling Value Play
- Seattle Genetics Shares Continue To Impress - And It's Not Too Late To Buy
- Not All Biotechnology ETFs Created Equal
- Protalix BioTherapeutics Finally Receives FDA Approval To Market Elelyso For Enzyme Replacement Therapy In Gaucher's Disease
- Coronado Biosciences: What Do The Recent Trial Changes Mean For Investors?
- LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?
- Coronado Biosciences: Phase II Trials Provide Multiple Shots On Goal
- Biotech Class Of 2010: IPOs Revisited
- Seattle Genetics: Innovative Biotech, Speculative Stock
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point
- Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials
- DUSA Pharmaceuticals Shares Tumble After Earnings: Low Growth Ahead?
- LPath Investors Have iSONEP Trial Results In Sight
- Raptor Pharmaceuticals Provides Update On Lead Candidate: RP103
- Savient Pharmaceuticals: Value Play Or Value Trap?
- Raptor Pharmaceuticals Announces Positive Phase 3 Trial Results: Shares Tumble
- iBio: Recent Lull Offers Opportunity to the Patient Investor
- Biotech Valuation Part 2: Market Size and rNPV Applied to Prolor Biotech
- Biotech Valuation Part 1: Science, Patents, and Management
- Prolor Biotech: Interim Phase 2 Data Promising
- DUSA Pharmaceuticals: Recent Pullback Provides Attractive Entry Point
- Ariad Pharmaceuticals and PACE: First Quarter Earnings Highlights
- Alternative Vaccine Manufacturers: Novavax and Ibio
- Raptor Pharmaceuticals: Pipeline Worth a Closer Look
- Depomed's Recent Events Boost Balance Sheet
- DUSA Pharmaceuticals: Small-Cap Biotech With a Healthy Cash Flow
- The Patent Cliff: What Big Pharma Investors Need to Know
- Why Phase 3 Trials Fail: What Investors Need to Know
- Earnings Analysis: Ariad Pharmaceuticals
